

ANTIBIOTICS, GI and RELATED AGENTS PRIOR AUTHORIZATION FORM (form effective 1/8/2024)

Prior authorization guidelines for Antibiotics, GI and Related Agents and Quantity Limits/Daily Dose Limits are available on the DHS Pharmacy Services website at <u>https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx</u>.

New request Renewal request	# of pages:	Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Beneficiary name:		City/State/Zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Drug requested:	Strength:	Dosage form:	
Dose/directions:		Quantity:	Refills:
Diagnosis (submit documentation):		Dx code (<i>required</i>):	I

Complete all sections that apply to the beneficiary and this request. Check all that apply and <u>submit documentation</u> for each item.

	INITIAL requests
1.	For treatment of HEPATIC ENCEPHALOPATHY: Has a history of trial and failure of or a contraindication or an intolerance to <u>lactulose</u>
2.	For treatment of TRAVELERS' DIARRHEA: Has a history of trial and failure of or a contraindication or an intolerance to <u>azithromycin</u>
3.	For treatment of IRRITABLE BOWEL SYNDROME WITH DIARRHEA:
4.	For treatment of SMALL INTENSTINAL BACTERIAL OVERGROWTH:
5.	For DIFICID (FIDAXOMICIN) for treatment of CLOSTRIDIOIDES DIFFICILE INFECTION: ☐ Has at least one of the following risk factors associated with a high risk of recurrence of Clostridioides difficile infection: ☐ 65 years of age or older ☐ Clinically severe Clostridioides difficile infection (Zar score ≥2) ☐ Immunocompromised status ☐ Has a recurrent episode of Clostridioides difficile infection ☐ Is prescribed Dificid (fidaxomicin) as a continuation of therapy upon inpatient discharge
6.	For ZINPLAVA (BEZLOTOXUMAB):
	Beneficiary's weight (in kg): kg

Requested medication is prescribed by or in consultation with a gastroenterologist or infection Has a recent stool test that is positive for toxigenic <i>Clostridioides difficile</i>	ous disease specialist			
Has at least one of the following factors associated with a high risk of recurrence of <i>Clostridi</i>	oides difficile infection:			
65 years of age or older				
Extended use of one or more systemic antibacterial drugs				
Clinically severe <i>Clostridioides difficile</i> infection				
At least one previous episode of <i>Clostridioides difficile</i> infection within the past six r	months			
Documented history of at least two previous episodes of <i>Clostridioides difficile</i> infe	ction			
Immunocompromised status				
Infected with a hypervirulent strain of <i>Clostridioides difficile</i> (ribotypes 027, 078, or	244)			
Will receive Zinplava (bezlotoxumab) in conjunction with an antibiotic regimen that is consist	ent with the standard of care for the			
treatment of Clostridioides difficile infection				
Has not received a prior course of treatment with Zinplava (bezlotoxumab)				
7. For ALL OTHER NON-PREFERRED Antibiotics, GI and Related Agents and for ALL OTHE	R INDICATIONS:			
Has a history of trial and failure of or a contraindication or an intolerance to the preferred An	tibiotics, GI and Related Agents that are			
approved or medically accepted for the treatment of the beneficiary's diagnosis	-			
RENEWAL requests				
1. For treatment of IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D):				
Had a successful initial treatment course				
Is experiencing recurrence of IBS-D symptoms				
Requested medication is prescribed by or in consultation with a gastroenterologist				
Request is for XIFAXAN (RIFAXIMIN) and:				
Has not received 3 or more treatment courses of Xifaxan (rifaximin) in the beneficia	ary's lifetime			
2. For treatment of SMALL INTESTINAL BACTERIAL OVERGROWTH:				
Requested medication is prescribed by or in consultation with a gastroenterologist				
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION				
Prescriber Signature:	Date:			

pennsylvania DEPARTMENT OF HUMAN SERVICES

<u>Confidentiality Notice</u>: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.